Blair William & Co. IL Raises Position in Axon Enterprise, Inc $AXON

Blair William & Co. IL increased its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 4.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 98,908 shares of the biotechnology company’s stock after buying an additional 4,391 shares during the quarter. Blair William & Co. IL owned about 0.13% of Axon Enterprise worth $70,980,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in shares of Axon Enterprise during the fourth quarter valued at approximately $480,000. NewEdge Advisors LLC lifted its position in shares of Axon Enterprise by 41.1% during the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after purchasing an additional 668 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of Axon Enterprise by 8.4% in the first quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after purchasing an additional 157 shares during the period. Woodline Partners LP boosted its stake in shares of Axon Enterprise by 40.6% in the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares during the period. Finally, Sivia Capital Partners LLC acquired a new stake in Axon Enterprise during the 2nd quarter valued at $284,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Trading Up 0.6%

AXON opened at $574.01 on Friday. Axon Enterprise, Inc has a 12-month low of $396.41 and a 12-month high of $885.91. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The stock has a market capitalization of $46.15 billion, a PE ratio of 377.64, a P/E/G ratio of 12.25 and a beta of 1.46. The firm’s fifty day moving average price is $536.08 and its 200 day moving average price is $617.87.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.55. The company had revenue of $796.72 million during the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period last year, the business earned $2.08 EPS. As a group, research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 revenue and bookings beat expectations — Axon reported quarterly revenue of ~$796.7M (up ~38.5% YoY) and said bookings were at record levels, driven by recurring software/services and AI products; investors are rewarding the growth narrative. Read More.
• Positive Sentiment: AI and acquisitions broaden the TAM — Axon is rolling out AI tools (Draft One) and expanding into emergency communications via buys like Carbyne and Prepared, pushing the company from hardware into a higher‑margin, recurring‑revenue public‑safety platform. Read More.
• Positive Sentiment: Hardware momentum in Connected Devices — demand for TASER 10, Axon Body 4 and counter‑drone solutions boosted device sales, helping current revenue strength and cross‑sell into Axon Cloud subscriptions. Read More.
• Neutral Sentiment: Street attention and bull narratives — multiple outlets and bullish newsletters have flagged Axon as a pick, increasing retail/institutional focus but also raising expectations. Read More.
• Negative Sentiment: Profitability collapsed despite revenue growth — quarterly net income plunged (reported near break‑even), compressing EPS and margins; that raises near‑term profitability and margin recovery questions. Read More.
• Negative Sentiment: Insider selling — Axon’s CAO sold 1,500 shares (~$860k), which may be viewed negatively by some investors even though the remaining insider stake remains material. Read More.
• Negative Sentiment: Analysts trimmed targets — some firms cut price targets (Morgan Stanley, Barclays) even as many maintain buy/overweight positions, signaling debate about valuation vs. execution. Read More.
• Negative Sentiment: High valuation and execution risk — AXON trades at a very high P/E, leaving the stock sensitive to execution on margin recovery, successful AI monetization and integration of acquisitions. Read More.

Insiders Place Their Bets

In related news, CFO Brittany Bagley sold 2,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the sale, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at $60,030,580. The trade was a 1.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the sale, the president directly owned 249,502 shares in the company, valued at approximately $137,874,805.20. This represents a 7.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 56,634 shares of company stock valued at $31,534,295. 4.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective for the company in a research report on Tuesday, January 6th. Royal Bank Of Canada dropped their target price on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Finally, Craig Hallum reissued a “buy” rating and issued a $820.00 price target on shares of Axon Enterprise in a report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.